Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.75 HKD | +0.15% |
|
-1.32% | +1.05% |
04-15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
04-15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.05% | 600M | |
+55.95% | 811B | |
+43.62% | 640B | |
-6.98% | 353B | |
+19.08% | 333B | |
+9.05% | 302B | |
+16.30% | 246B | |
+2.41% | 225B | |
+12.47% | 218B | |
+8.91% | 168B |
- Stock Market
- Equities
- 1477 Stock
- News Ocumension Therapeutics
- Ocumension Says Core Product Added to China's National Reimbursement Drug List